Immunology & Autoimmune
Part of Biotech - Drug Development
 JNJ | Johnson & Johnson | $0.7t | $267.64 | +0.0% | 3.5M |
 ABBV | ABBVIE INC. | $462.5b | $262.00 | -0.2% | 2.2M |
 AMGN | Amgen Inc | $239.4b | $377.47 | +0.2% | 1.4M |
 BMY | Bristol-Myers Squibb Co. | $138.2b | $63.69 | -0.2% | 5.8M |
 REGN | Regeneron Pharmaceuticals Inc | $86.8b | $781.08 | +0.1% | 263.0K |
 ROIV | Roivant Sciences Ltd. Common Shares | $24.9b | $40.49 | +0.2% | 5.1M |
 APGE | Apogee Therapeutics, Inc. Common Stock | $10.2b | $135.09 | 0.0% | N/A |
 PTGX | Protagonist Therapeutics, Inc | $9.6b | $142.80 | -0.4% | 361.7K |
 TGTX | TG Therapeutics, Inc. | $8.7b | $55.83 | +5.2% | 2.0M |
 IBRX | ImmunityBio, Inc. Common Stock | $8.4b | $7.94 | -2.7% | 7.6M |
 IMVT | Immunovant, Inc. Common Stock | $8.2b | $37.50 | -0.7% | 810.4K |
 SYRE | Spyre Therapeutics, Inc. Common Stock | $7.7b | $91.19 | +0.3% | 694.7K |
 ORKA | Oruka Therapeutics, Inc. Common Stock | $6.0b | $93.60 | +1.5% | 578.0K |
 DNTH | Dianthus Therapeutics, Inc. Common Stock | $5.9b | $102.61 | -2.2% | 661.1K |
 APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
 RCUS | Arcus Biosciences, Inc. | $3.8b | $24.55 | +1.4% | 1.9M |
 CLDX | Celldex Therapeutics, Inc | $3.1b | $38.70 | +0.5% | 851.1K |
 ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $3.0b | $26.13 | +11.3% | 4.6M |
 NKTR | Nektar Therapeutics | $2.6b | $67.22 | +1.1% | 617.5K |
 VERA | Vera Therapeutics, Inc. Class A Common Stock | $2.5b | $31.73 | -5.8% | 3.7M |
 BHVN | Biohaven Ltd. | $2.4b | $12.12 | -1.0% | 1.9M |
 AUPH | Aurinia Pharmaceuticals Inc | $2.2b | $16.82 | +5.2% | 923.0K |
 ZBIO | Zenas BioPharma, Inc. Common Stock | $2.1b | $32.00 | +1.3% | 561.0K |
 ADMA | ADMA Biologics, Inc. | $2.1b | $8.80 | +3.5% | 2.0M |
 XNCR | Xencor, Inc. | $2.0b | $23.69 | -0.3% | 657.1K |
 SEPN | Septerna, Inc. Common Stock | $1.7b | $38.44 | -1.3% | 219.4K |
 ANAB | AnaptysBio, Inc. Common Stock | $1.7b | $54.29 | -0.7% | 295.5K |
 FBRX | Forte Biosciences, Inc. Common Stock | $1.6b | $76.98 | 0.0% | N/A |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.4b | $20.63 | +0.2% | 671.2K |
 JBIO | Jade Biosciences, Inc. Common Stock | $1.4b | $16.64 | -4.3% | 1.6M |
 ALMS | Alumis Inc. Common Stock | $1.3b | $8.03 | -5.8% | 3.8M |
 MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.3b | $12.43 | +2.4% | 2.2M |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.2b | $12.40 | -5.6% | 762.3K |
 AVTX | Avalo Therapeutics, Inc. Common Stock | $1.0b | $16.57 | +3.1% | 1.3M |
 IMMX | Immix Biopharma, Inc. Common Stock | $1.0b | $12.21 | -1.7% | 1.3M |
 ANNX | Annexon, Inc. Common Stock | $0.9b | $3.91 | +0.1% | 3.7M |
 ACRS | Aclaris Therapeutics, Inc. | $0.9b | $5.37 | -3.6% | 5.4M |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $44.63 | +0.2% | 171.6K |
 CLYM | Climb Bio, Inc. Common Stock | $0.9b | $13.96 | +1.4% | 2.3M |
 DBVT | DBV Technologies S.A. | $0.9b | $11.78 | +0.6% | 150.4K |
 STTK | Shattuck Labs, Inc. Common Stock | $0.7b | $5.72 | -1.7% | 574.5K |
 CABA | Cabaletta Bio, Inc. Common Stock | $0.6b | $2.57 | -4.4% | 5.4M |
 ZURA | Zura Bio Limited Class A Ordinary Shares | $0.6b | $4.86 | -6.1% | 920.7K |
 KYTX | Kyverna Therapeutics, Inc. Common Stock | $0.5b | $6.95 | -0.7% | 567.9K |
 EVMN | Evommune, Inc. | $452.9m | $9.53 | -6.2% | 504.3K |
 ENTA | Enanta Pharmaceuticals, Inc | $410.4m | $12.72 | +3.6% | 227.4K |
 IPSC | Century Therapeutics, Inc. Common Stock | $382.1m | $1.86 | -5.1% | 709.9K |
 QTTB | Q32 Bio Inc. Common Stock | $381.0m | $11.19 | -1.3% | 448.7K |
 PALI | Palisade Bio, Inc. Common Stock | $356.4m | $1.74 | -16.6% | 6.7M |
 SABS | SAB Biotherapeutics, Inc. Common Stock | $338.5m | $3.38 | -0.7% | 397.2K |